SEC Form 3 FORM 3

UNITED STATES SECURITIES AND EXCHANGE

COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

3235-OMB Number: 0104

Estimated average burden hours per 0.5 response

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] Ellis Christopher		Requiring (Month/Da	2. Date of Event Requiring Statement (Month/Day/Year) 04/29/2021 3. Issuer Name and Ticker or Trading Symbol Vaccitech plc [VACC]					
(Last)(First)(Middle)C/O VACCITECH PLC, THE SCHRODINGER BLDGHEATLEY ROAD, THE OXFORD SCIENCE PARK(Street) OXFORD0X4 4GE(City)(State)(Zip)				4. Relationship of Reporting Issuer (Check all applicable) Director X Officer (give title below) Chief Operating	10% O Other (below)	wner (specify 6. (C	led (Month/Day/ Individual or Jo heck Applicable X Form filed Person	int/Group Filing e Line) by One Reporting by More than One
	Т	able I - Nor	n-Derivati	ive Securities Benefic	cially Ov	vned		
1. Title of Security (Instr. 4)			I	2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)		Direct Own	4. Nature of Indirect Beneficial Ownership (Instr. 5)	
	(e.ç			e Securities Beneficia nts, options, converti				
		2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of	5. Ownership Form: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr.
		Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative or Indirect Security (I) (Instr. 5)		5)
Share Option (Right	t to Buy)	(1)	02/16/2028	Ordinary Shares ⁽²⁾	50,985	0.0004(1)	D	
Share Option (Right	t to Buy)	(3)	02/16/2028	Ordinary Shares ⁽²⁾	18,540	0.0004 ⁽³⁾	D	
Share Option (Right	t to Buy)	(4)	01/21/2029	Ordinary Shares ⁽²⁾	30,900	0.0004 ⁽⁴⁾	D	
Share Option (Right	t to Buy)	(5)	08/14/2029	Ordinary Shares ⁽²⁾	9,270	0.0004 ⁽⁵⁾	D	
Share Option (Right	t to Buy)	(6)	01/08/2030	Ordinary Shares ⁽²⁾	12,360	0.0004(6)	D	
Share Option (Right	t to Buy)	(7)	02/12/2031	Ordinary Shares ⁽²⁾	30,900	0.0001(7)	D	

Explanation of Responses:

1. This option is fully vested and exercisable as of the date hereof. The exercise price of this option is GBP 0.000324 per share and has been converted from pounds sterling to U.S. dollars using an average exchange rate of \$1.3269 to GBP 1.00 on December 31, 2019.

2. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

3. This option shall vest and become exercisable in four equal annual installments, with the first installment vested on February 1, 2019. The exercise price of this option is GBP 0.000324 per share and has been converted from pounds sterling to U.S. dollars using an average exchange rate of \$1.3269 to GBP 1.00 on December 31, 2019.

4. This option shall vest and become exercisable in four equal annual installments, with the first installment vested on March 1, 2019. The exercise price of this option is GBP 0.000324 per share and has been converted from pounds sterling to U.S. dollars using an average exchange rate of \$1.3269 to GBP 1.00 on December 31, 2019.


5. This option shall vest and become exercisable in four equal annual installments, with the first installment vested on February 1, 2020. The exercise price of this option is GBP 0.000324 per share and has been converted from pounds sterling to U.S. dollars using an average exchange rate of \$1.3269 to GBP 1.00 on December 31, 2019.

6. This option shall vest and become exercisable in four equal annual installments, with the first installment vested on January 1, 2021. The exercise price of this option is GBP 0.000324 per share and has been converted from pounds sterling to U.S. dollars using an average exchange rate of \$1.3662 to GBP 1.00 on December 31, 2020.

7. This option shall vest and become exercisable in four equal annual installments, with the first installment vesting on January 1, 2022. The exercise price of this option is GBP 0.000032 per share and has been converted from pounds sterling to U.S. dollars using an average exchange rate of \$1.3662 to GBP 1.00 on December 31, 2020.

Remarks:

Exhibit 24 - Power of Attorney



04/29/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of William Enright, Georgy Egorov, Robert E. Puopolo and Marishka DeToy, signing singly, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Vaccitech plc, a corporation of England and Wales (the "**Company**"), (i) Forms 3, 4 and 5, (ii) Schedule 13D, (iii) Schedule 13G and (iv) amendments of each thereof, in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5, Schedule 13D, Schedule 13G or any amendments thereto and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorneyin-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-infact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned 's responsibilities to comply with Section 16 or Regulation 13D-G of the Securities Exchange Act of 1934, as amended. The undersigned hereby agrees to indemnify the attorney-in-fact and the Company from and against any demand, damage, loss, cost or expense arising from any false or misleading information provided by the undersigned to the attorney-in-fact.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. This Power of Attorney may be filed with the United States Securities and Exchange Commission as a confirming statement of the authority granted herein. This Power of Attorney supersedes any prior power of attorney in connection with the undersigned's capacity as an officer and/or director of the Company. This Power of Attorney shall expire as to any individual attorney-in-fact if such attorney-in-fact ceases to be an executive officer of the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of April 29, 2021.

/s/ Christopher Ellis Christopher Ellis